132 related articles for article (PubMed ID: 38117940)
1. Identification of novel sulfathiazole-triazolo-chalcone hybrids as VEGFR-2/EGFR dual inhibitors with antiangiogenic activity and apoptotic induction.
Zeidan MA; Othman DIA; Goda FE; Mostafa AS
Arch Pharm (Weinheim); 2024 Mar; 357(3):e2300320. PubMed ID: 38117940
[TBL] [Abstract][Full Text] [Related]
2. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
4. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
5. Identification of new benzimidazole-triazole hybrids as anticancer agents: multi-target recognition,
Othman DIA; Hamdi A; Tawfik SS; Elgazar AA; Mostafa AS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166037. PubMed ID: 36651111
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Antiproliferative Activity of Quinazolin-4-One/Chalcone Hybrids
Hisham M; Hassan HA; Gomaa HAM; Youssif BGM; Hayalah AM; Abdel-Aziz M
Anticancer Agents Med Chem; 2023; 23(17):1932-1943. PubMed ID: 37497685
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and modelling study of new 1,2,3-triazole/chalcone hybrids with antiproliferative action as epidermal growth factor receptor inhibitors.
Maghraby MT; Salem OIA; Youssif BGM; Sheha MM
Chem Biol Drug Des; 2023 Mar; 101(3):749-759. PubMed ID: 36366966
[TBL] [Abstract][Full Text] [Related]
8. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
[TBL] [Abstract][Full Text] [Related]
9. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
Ahmed MF; Santali EY; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin/EGFR kinase inhibition.
Amin MM; Abuo-Rahma GEA; Shaykoon MSA; Marzouk AA; Abourehab MAS; Saraya RE; Badr M; Sayed AM; Beshr EAM
Bioorg Chem; 2023 May; 134():106444. PubMed ID: 36893547
[TBL] [Abstract][Full Text] [Related]
11. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
12. Exploring the anticancer properties of a new nicotinamide analogue: Investigations into in silico analysis, antiproliferative effects, selectivity, VEGFR-2 inhibition, apoptosis induction, and migration suppression.
Eissa IH; Yousef RG; Sami M; Elkaeed EB; Alsfouk BA; Ibrahim IM; Husein DZ; Elkady H; Metwaly AM
Pathol Res Pract; 2023 Dec; 252():154924. PubMed ID: 37956639
[TBL] [Abstract][Full Text] [Related]
13. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile.
Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701
[TBL] [Abstract][Full Text] [Related]
14. New 1,3,4-oxadiazole-chalcone/benzimidazole hybrids as potent antiproliferative agents.
Hagar FF; Abbas SH; Abdelhamid D; Gomaa HAM; Youssif BGM; Abdel-Aziz M
Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200357. PubMed ID: 36351754
[TBL] [Abstract][Full Text] [Related]
15. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation.
Azab AE; Alesawy MS; Eldehna WM; Elwan A; Eissa IH
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200133. PubMed ID: 35822666
[TBL] [Abstract][Full Text] [Related]
16. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
18. Novel antiproliferative agents bearing substituted thieno[2,3-d]pyrimidine scaffold as dual VEGFR-2 and BRAF kinases inhibitors and apoptosis inducers; design, synthesis and molecular docking.
Hassan RA; Hamed MIA; Abdou AM; El-Dash Y
Bioorg Chem; 2022 Aug; 125():105861. PubMed ID: 35569190
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
20. Exploration of antiproliferative potential of modified triazole-benzohydrazone scaffold: Multitarget approach.
Ali AM; Khalaf MA; Bhongade BA; Selim KB; Mostafa AS
Arch Pharm (Weinheim); 2024 Feb; 357(2):e2300383. PubMed ID: 37946599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
